The FDA's Critical Path Initiative is useful for device companies too
This article was originally published in Clinica
Executive Summary
Effectiveness tools for devices is to be a theme in the US FDA's upcoming report on progress with its regulatory efficiency initiative. This applies to device as well as drug companies, says US editor Karen Riley